Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Internal Medicine | Neurology | Pathology | Pediatrics | Psychiatry | Journal

Back to Journal Articles

Marijuana-Like Chemical Corrects Behavior in Fragile X

Last Updated: September 25, 2012.

 

Endocannabinoid mediated process is absent in fragile X mental retardation

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The protein lost in fragile X syndrome, the most common genetic cause of autism, is part of a complex that, when targeted by a drug that boosts a natural marijuana-like chemical in the brain, corrects some of the behavioral abnormalities in mice, according to a study published online Sept. 25 in Nature Communications.

TUESDAY, Sept. 25 (HealthDay News) -- The protein lost in fragile X syndrome, the most common genetic cause of autism, is part of a complex that, when targeted by a drug that boosts a natural marijuana-like chemical in the brain, corrects some of the behavioral abnormalities in mice, according to a study published online Sept. 25 in Nature Communications.

Noting that the fragile X mental retardation protein (FMRP) is lost in patients with fragile X syndrome, and that FMRP regulates signal transduction at metabotropic glutamate receptor-5 (mGlu5) in the brain, Kwang-Mook Jung, Ph.D., from the University of California in Irvine, and colleagues examined whether FMRP deletion affected mGlu5-dependent signaling by the retrograde endocannabinoid transmitter, 2-arachidonoyl-sn-glycerol (2-AG), in mice.

The researchers found that mGlu5-dependent long-term depression at excitatory synapses of the ventral striatum and prefrontal cortex was absent in the mice due to disruption of the complex linking mGlu5 to 2-AG formation. Enhancing 2-AG signaling by small molecules restored endocannabinoid-dependent long-term depression and corrected behavioral abnormalities.

"In conclusion, our results indicate that FMRP expression is necessary for the correct assembling of the endocannabinoid signalosome at glutamatergic synapses of the frontal cortex and ventral striatum core, and identify this macromolecular complex as a previously unknown substrate for fragile X syndrome, which might be targeted by therapy," Jung and colleagues write.

Full Text

Copyright © 2012 HealthDay. All rights reserved.


Previous: Watch & Wait OK in Low-Tumor Burden Follicular Lymphoma Next: BPA Alters Oogenesis and Follicle Formation in Primates

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.